OPTINOSE INC. - COMMON STOCK

Optinose to Present at the Needham Virtual Healthcare Conference

04 Apr 2024 16:01:00 By Nasdaq GlobeNewswire

XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps

15 Mar 2024 15:34:50 By Nasdaq GlobeNewswire

Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

07 Mar 2024 07:00:43 By Nasdaq GlobeNewswire

Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results

29 Feb 2024 16:40:00 By Nasdaq GlobeNewswire

Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice

18 Jan 2024 12:00:00 By Nasdaq GlobeNewswire

Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE

06 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference

22 Nov 2023 09:00:00 By Nasdaq GlobeNewswire

Optinose Reports Third Quarter 2023 Financial Results and Operational Updates

09 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Optinose Announces Reporting Date for Third Quarter 2023 Financial Results

27 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Optinose to Present at the 2023 Cantor Global Healthcare Conference

22 Sep 2023 09:01:00 By Nasdaq GlobeNewswire

Optinose Reports Second Quarter 2023 Financial Results and Operational Updates

10 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million

27 Jul 2023 07:00:01 By Nasdaq GlobeNewswire

Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

16 Jun 2023 16:08:00 By Nasdaq GlobeNewswire

Optinose to Present at the Jefferies Healthcare Conference

02 Jun 2023 13:00:00 By Nasdaq GlobeNewswire

Optinose Reports First Quarter 2023 Financial Results and Operational Updates

11 May 2023 07:00:18 By Nasdaq GlobeNewswire

Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE

04 May 2023 07:00:01 By Nasdaq GlobeNewswire

Optinose Announces Reporting Date for First Quarter 2023 Financial Results

01 May 2023 16:30:00 By Nasdaq GlobeNewswire

Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

18 Apr 2023 08:00:01 By Nasdaq GlobeNewswire

Optinose to Present at the Needham Virtual Healthcare Conference

12 Apr 2023 16:00:00 By Nasdaq GlobeNewswire

Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights

07 Mar 2023 07:00:56 By Nasdaq GlobeNewswire